Results of Operations and Financial Condition. On August 14, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Entry into a Material Definitive Agreement. On July 31, 2026, Moleculin Biotech, Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “Placement Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) for the public offering (the “Offering”) by the Company of (i) an aggregate of 12,376,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), or pre-funded warrants in lieu thereof (the “Pre-Fun…

Results of Operations and Financial Condition. On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Results of Operations and Financial Condition. On March 19, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Unregistered Sales of Equity Securities The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares will be registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state…

Entry into a Material Definitive Agreement. On February 19, 2026, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (each, an “Inducement Letter”) with holders of certain existing warrants (the “Holders”) to purchase up to 2,122,652 shares of Company common stock with an exercise price of $3.90 per share (the “Existing Warrants”). Pursuant to the Inducement Letter, the Holders agreed to exercise the Existing Warrants, and the Company agreed to issu…

Entry into a Material Definitive Agreement. On December 21, 2025, Moleculin Biotech, Inc. (the “Company”) entered into separate warrant amendment agreements (collectively, the “Warrant Amendment”) with the holders of the Company’s Series E warrants (the “Series E warrants”), Series F warrants (the “Series F warrants”), and Series G warrants (the “Series G warrants,” and collectively with the Series E warrants and Series F warrants, the “Warrants”). Pursuant to the Warrant Amendment, (A) the W…

Entry into a Material Definitive Agreement. On December 9, 2025, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with: (i) the holder of existing Series C warrants and Series D warrants to purchase an aggregate of up to 727,969 shares of Company common stock, pursuant to which the holder agreed to exercise the warrants at a reduced exercise price of $6.63 per share; and (ii) the holders of certain existing Series F warr…

Unregistered Sales of Equity Securities The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), available under Section 4(a)(2) thereof. Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares will be registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registratio…

Material Modifications of Rights of Security Holders. To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on May 23, 2025, Moleculin Biotech, Inc. (the “Company”) received a letter from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it did not comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in sto…

Unregistered Sales of Equity Securities The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares will be registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state…

Entry into a Material Definitive Agreement On August 27, 2025, Moleculin Biotech, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with holders of certain existing warrants (the “Holders”) to purchase up to 16,216,216 shares of Company common stock with an exercise price of $0.37 per share (the “Existing Warrants”). Pursuant to the Inducement Letter, the Holders agreed to exercise the Existing Warrants, and the Company agreed to issue the…

Results of Operations and Financial Condition. On August 13, 2025, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Entry into a Material Definitive Agreement. On July 11, 2025, Moleculin Biotech, Inc. (the “Company”), entered into an At The Market Offering Agreement (the “ATM Agreement”) with Roth Capital Partners, LLC (“Roth Capital”). Pursuant to the terms of the ATM Agreement, the Company may sell from time to time through Roth Capital, as sales agent and/or principal, shares of the Company’s common stock, par value $0.001 per share (“Shares”) with an aggregate sales price of up to $6,500,000. The Comp…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 27, 2025, Moleculin Biotech, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capit…

Entry into a Material Definitive Agreement. Securities Purchase Agreements On June 20, 2025, Moleculin Biotech, Inc. (the “Company”) commenced a best efforts public offering (the “Offering”) of (i) 9,972,026 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”); (ii) pre-funded warrants to purchase up to an aggregate of 6,107,974 shares of Common Stock (the “Pre-Funded Warrants”); and (iii) Series E Warrants to purchase up to an aggregate of 48,240,0…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 23, 2025, Moleculin Biotech, Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in st…

Results of Operations and Financial Condition. On May 14, 2025, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Results of Operations and Financial Condition. On March 24, 2025, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2024 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. On February 25, 2025, Moleculin Biotech, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with an institutional investor (the “Investor”) for the sale by the Company of 1,150,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, and pre-funded warrants to purchase 2,121,029 shares of common stock (the “Pre-Funded Warrants”) in a registered direct offering (the “Offering”). In…

Entry into a Material Definitive Agreement. On February 13, 2025, Moleculin Biotech, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with a holder of certain existing warrants (“Holder”) to receive new warrants (the “Inducement Warrants”) to purchase up to a number of shares of common stock equal to 200% of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase up to 5,828,570 shares of…

Unregistered Sales of Equity Securities The Company will issue the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2). Neither the issuance of the Inducement Warrants nor the Inducement Warrant Shares will be registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable st…

Entry into a Material Definitive Agreement. On February 9, 2025, Moleculin Biotech, Inc. (the “Company”) entered into a waiver and consent agreement (the “Waiver”) with an investor from the Company’s offering completed August 19, 2024 pursuant to which the investor waived certain restrictions related to the Company’s ability to enter into a “Variable Rate Transaction.” Pursuant to the Waiver, the Company agreed to: (i) to reduce the exercise price of certain warrants held by the investors to…